In patients with progressive metastatic neuroendocrine tumors, median survival in the octreotide monotherapy arm was 32 months.
In plain wordsIn patients with metastatic neuroendocrine tumors, median survival in the octreotide-only group was 32 months.
- Peptide
- Octreotide
- Outcome
- Not applicableMedian survival
- Study
n = 51
- Outcome group
- Mortality · Cancer
- Studied dose
- Dose not stated
Measurements
- Median survival
- 32 months
- octreotide monotherapy arm
Source sentences
Time to treatment failure and long-term survival did not differ significantly between the 2 groups, with a median survival of 32 and 54 months for the octreotide and the combination groups, respectively.
2 context sentences(design, population, supporting numbers)
The effect of octreotide plus interferon-alpha versus octreotide monotherapy on the primary study end points of time to treatment failure (progression, death, stop of study treatment) and long-term survival was investigated in patients with progressive metastatic neuroendocrine foregut (mainly pancr…
One hundred nine of 125 registered patients were randomized starting in January 1995, and 105 patients (51 monotherapy, 54 combination treatment) were finally analyzed in March 2000.